Albany Molecular Research, Inc. (AMRI) to Present Obesity Compound Phase I Clinical Results

ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) will present results from a Phase 1 clinical study with its Melanin Concentrating Hormone Receptor 1 (MCH1) antagonist, ALB-127158(a), at the 18th European Congress on Obesity (ECO2011, May 25-28, 2011, Istanbul, Turkey).